David Adams is a Senior Group Leader at the Wellcome Trust Sanger Institute. By developing and applying new genomic technologies and experimental model systems, Dr Adams has redefined our understanding of key processes that control tumour growth, metastasis and predisposition to tumour formation. He has also generated the largest ever collection of genetically modified mouse lines which have been distributed to researchers around the globe facilitating key insights in areas such as brain and bone development, infection and immunology, and metabolism. Dr Adams also leads the mouse genomes project which has sequenced and analysed over 40 mouse strains and released these data to the research community.
FellowBack to directory listing
Dr David Adams FMedSci
Senior Group Leader
Cancer Ageing and Somatic Mutation
Wellcome Trust Sanger Institute
Cancer genetics, functional genomics, gene editingSection committee elected by
Cellular and developmental biology, microbiology and immunology, genetics